Ornidazole-Astrapharm
Release Forms:
Composition:
- active substance: ornidazole;
- 1 capsule contains ornidazole in terms of 100% of the substance 500 mg;
- excipients: potato starch, magnesium stearate;
- the composition of the capsule shell: gelatin, titanium dioxide (E 171), indigo carmine blue 2 (E 132), azorubin (E 122).
Dosage form. Capsules.
Main physical and chemical properties: hard gelatin capsules № 0 cylindrical with hemispherical ends, body – white, lid – blue. The contents of the capsules are a pale yellow crystalline powder.
10 capsules in a blister; 1 blister in a box.
Trichomoniasis (urogenital infections in women and men caused by Trichomonas vaginalis).
Amoebiasis (all intestinal infections caused by Entamoeba histolytica, including amoebic dysentery,
all extraintestinal forms of amebiasis, especially amoebic liver abscess).
Giardiasis.
Contraindications.
Hypersensitivity to ornidazole or other components of the drug or to other nitroimidazole derivatives. Lesions of the central nervous system (epilepsy, brain damage, multiple sclerosis); pathological blood lesions, or other hematological abnormalities.
Ornidazole should always be taken orally after a meal. Patients with renal insufficiency: no dose adjustment is required for patients with renal impairment. Patients with hepatic insufficiency: the interval should be twice as long for patients with severe hepatic insufficiency. Elderly patients: no clinical data are available on the use in elderly patients.
Trichomoniasis: 500 mg capsules are used in single or 5-day therapy regimens.
Ornidazole may cause reactions such as redness, numbness, fever, nausea, and vomiting, as well as possible hypotension and tinnitus. Alcohol should not be consumed for at least 3 days after taking the drug.